Maravai LifeSciences Holdings MRVI 深 沪
等待开盘 07-18 09:30:00 美东时间
2.51
-0.010
-0.40%
华盛通- 最 高2.60
- 今 开2.53
- 成交量 121.89万股
- 最 低 2.45
- 昨 收 2.52
- 总市值 3.61亿
- 52周最高 10.03
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 1.665
- 委 比 -18.15%
- 总股本 1.44亿
- 历史最高 63.55
- 量 比 0.74
- 振 幅 5.95%
- 历史最低 1.665
- 每 手 1
- 风险率 2.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Maravai Lifesciences appoints Rajesh Asarpota as chief financial officer
Maravai LifeSciences (NASDAQ:MRVI) announced that Rajesh Asarpota has been appointed executive vice president and chief financial officer effective June 30, 2025. He will succeed Kevin Herde, who is t...
06-26 04:08
Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer
Maravai LifeSciences Holdings, Inc. has appointed Rajesh "Raj" Asarpota as Executive Vice President and Chief Financial Officer, effective June 30, 2025, succeeding Kevin Herde, who will transition to an advisory role. Asarpota, with over three decades of experience in finance and leadership roles across life sciences and medical device companies, will lead Maravai’s global Finance, Accounting, Treasury, Investor Relations, Corporate Strategy, an...
06-25 20:01
Maravai LifeSciences Announces The Appointment Of Bernd Brust As Chief Executive Officer, Effective Immediately
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer
06-09 20:36
Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors
Maravai LifeSciences has appointed Bernd Brust as CEO and Board member, succeeding William “Trey” Martin III. Brust, with over 30 years of experience in the life sciences industry, is expected to drive innovation and financial growth. The company remains focused on expanding its leadership in mRNA and bioprocess technologies, supporting customers from discovery to commercialization. Maravai will reassess its 2025 financial outlook during the Q2 e...
06-09 12:30
TriLink and IVI Collaborate To Advance Research And Development Of mRNA-Based Vaccines And Promote Equitable Access To Essential Vaccines And Health Technologies
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit
05-15 04:03
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Baird Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $2
Baird analyst Catherine Schulte maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and lowers the price target from $3 to $2.
05-13 20:30
Maravai LifeSciences Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $46.85M Beat $44.01M Estimate
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 300 percent decrease over losses of $(0.02) per share
05-13 04:08
Earnings Scheduled For May 12, 2025
Companies Reporting Before The Bell • Superior Industries Intl (NYSE:SUP) is pr...
05-12 16:32
